Litigation Details for Bayer Pharma AG v. Accord Healthcare Inc. (D. Del. 2021)

Bayer Pharma AG v. Accord Healthcare Inc. (D. Del. 2021)

Docket		Date Filed	2021-04-22
Court	District Court, D. Delaware	Date Terminated	2021-07-29
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,828,310
Link to Docket	External link to docket

Details for Bayer Pharma AG v. Accord Healthcare Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-22				External link to document

Litigation summary and analysis for: Bayer Pharma AG v. Accord Healthcare Inc. (D. Del. 2021)

Last updated: July 26, 2026

Bayer Pharma AG v. Accord Healthcare Inc. (1:21-cv-00566): Litigation Summary, Patent Issues, and Generic Launch Risk Analysis

Bayer Pharma AG v. Accord Healthcare Inc., No. 1:21-cv-00566, is an ANDA patent-infringement case targeting Accord’s proposed generic entry. The docket establishes a Hatch-Waxman framework, with the core business risk centered on whether Bayer’s asserted Orange Book patents can withstand validity and non-infringement defenses, and on timing pressure created by any court schedule tied to generic commercialization.

What is the procedural posture of Bayer Pharma AG v. Accord Healthcare Inc. (1:21-cv-00566)?

Featured-snippet answer: The case is a Hatch-Waxman ANDA infringement suit filed in 2021, alleging that Accord’s ANDA submission infringes one or more Bayer-listed Orange Book patents for the branded product.

Case identifiers and court

• Caption: Bayer Pharma AG v. Accord Healthcare Inc.
• Docket: 1:21-cv-00566
• Jurisdiction: Federal district court (Hatch-Waxman ANDA patent litigation)

Typical posture in this docket class (what to expect)

• Bayer files suit within the statutory window after receiving notice tied to an ANDA Paragraph certification.
• Accord answers with non-infringement, invalidity, and procedural defenses.
• The case proceeds through claim construction, expert discovery, and dispositive motions, often followed by trial or settlement.

What patents are asserted in Bayer Pharma AG v. Accord Healthcare Inc. (1:21-cv-00566)?

Featured-snippet answer: The asserted patents are the specific Orange Book-listed patents identified in the Hatch-Waxman notice that triggered the suit, typically including one or more of formulation, method-of-use, and/or device-delivery system patents depending on the listed patent families for the reference product.

Asserted-patent estate mapping (how this case is analyzed)

Because this request is limited to “litigation summary and analysis” and does not provide the asserted patent numbers, claim lists, or the brand name targeted, a complete, accurate patent-by-patent analysis cannot be produced.

How does the complaint frame infringement and claim scope?

Featured-snippet answer: Hatch-Waxman complaints typically plead infringement of asserted claims of the Orange Book patents under the ANDA “reasonably expected to result” standard, using the ANDA label and description of the proposed product.

Infringement theory elements in this case category

• Bayer asserts that Accord’s proposed generic product meets claim limitations for the asserted Orange Book claims.
• Bayer ties claim elements to Accord’s ANDA-described manufacturing, formulation, or use instructions.
• Bayer often supports infringement with technical experts and references to the ANDA product’s proposed composition or performance.

What defenses does Accord typically raise in ANDA patent cases like this?

Featured-snippet answer: Common defenses include non-infringement (claim construction and product differences), invalidity (anticipation, obviousness, lack of written description, indefiniteness), and procedural defenses tied to compliance with ANDA notice requirements.

Non-infringement themes (typical)

• Differences in formulation parameters, dosage form attributes, or active ingredient characteristics.
• Non-matching claim limitations after claim construction.

Invalidity themes (typical)

• Prior art patents and publications that anticipate or render claims obvious.
• Attacks on claim definiteness, enablement, and written description.
• Obviousness combinations centered on genericization arguments and known delivery/formulation knowledge.

Procedural and notice-related issues (typical)

• Challenges to whether the ANDA notice was adequate under Hatch-Waxman.
• Defenses tied to the timing and scope of the asserted patents.

What does the litigation timeline imply for exclusivity and generic entry?

Featured-snippet answer: The schedule is the commercial lever. If Bayer wins early on claim construction or dispositive invalidity/non-infringement, Accord’s entry window shifts; if validity and infringement issues survive, the case tends to move toward trial or settlement.

Business timing levers to track in this docket

• Claim construction order dates
• Expert discovery deadlines
• Motions for summary judgment
• Trial scheduling (or settlement signals)
• Any court stay relating to other related actions

What is the settlement and injunction risk profile for a generic challenger?

Featured-snippet answer: Settlement risk is tied to (i) strength of Bayer’s asserted claims, (ii) how the court construes key limitations, and (iii) whether Accord’s design around or label carve-out plausibly avoids infringement.

Settlement structures common in ANDA cases

• License with payment in exchange for non-infringement entry timing.
• Damages-only resolution without an early entry deal.
• Covenant-not-to-sue terms that enable entry after a specific date.

Injunction exposure

• If Bayer proves infringement and validity, Bayer can seek an injunction blocking ANDA approval/launch as barred by 35 U.S.C. § 271(e)(2) framework and the Hatch-Waxman remedy structure.

Does this case affect FDA exclusivity or only the patent barrier?

Featured-snippet answer: The case primarily targets the patent barrier. FDA exclusivity (e.g., 5-year/3-year exclusivity or regulatory exclusivities tied to the reference product) is distinct from patent litigation, though both can delay approval and launch.

How to separate the barriers in Hatch-Waxman

• Patent litigation: blocks approval/launch based on infringement findings as to listed patents.
• Exclusivity: blocks approval even if patents are cleared, until exclusivity ends.

What is the Orange Book status angle for Bayer’s position?

Featured-snippet answer: Bayer’s Orange Book listings determine which patents are litigable and which certifications (Paragraph IV, I, II, III) triggered suit.

Orange Book-linked diligence items

• Which patents are listed for the reference product
• Their expiration dates and any terminal disclaimers
• Whether patents cover formulation, method-of-use, or packaging/device attributes

How strong is the patent estate in Bayer Pharma AG v. Accord Healthcare Inc.?

Featured-snippet answer: Strength cannot be quantified without the asserted patent numbers, claim charts, or claim construction outcomes.

Scoring model used in practice (what would be assessed)

• Claim breadth at construction
• Prior art density and relevance
• Written description/enablement robustness
• Secondary considerations (if raised)
• Litigation history of the same patent family in other ANDA cases

Which parties are involved beyond Bayer and Accord?

Featured-snippet answer: In this docket class, the core parties are the NDA holder/patent owner and the generic ANDA filer, often with additional named defendants or corporate entities only if they are the ANDA labeler or sponsor.

What to check in the docket (litigation architecture)

• Whether additional defendants exist (labeler, distributor, affiliate)
• Whether the ANDA filer is the same entity as named in the suit
• Whether co-pending cases involve the same patents across multiple filers

What generic entry risks exist for Accord after (or during) this litigation?

Featured-snippet answer: Entry risk turns on whether Accord’s ANDA can be designed around or the asserted patents can be invalidated or found not infringed.

Design-around risk drivers

• Whether the accused generic can change formulation parameters without affecting bioequivalence
• Whether method-of-use claim avoidance is feasible via label restrictions
• Whether the formulation is locked by bioequivalence constraints

“All patents not asserted” reality

In ANDA litigation, even if some asserted claims fail, remaining asserted patents can still block entry.

---

Key Takeaways

• Bayer v. Accord Healthcare Inc. (1:21-cv-00566) is an ANDA Hatch-Waxman patent infringement action centered on Orange Book patents tied to Accord’s proposed generic entry.
• The commercial impact is determined by court outcomes on claim scope, validity, and infringement, which control whether an injunction blocks launch or whether Accord can enter.
• A complete patent-by-patent litigation summary (asserted numbers, asserted claims, claim construction results, and outcome) cannot be produced from the docket identifier alone.

---

FAQs

1. How are “Paragraph IV” certifications reflected in ANDA infringement suits like Bayer v. Accord?
2. What court milestones most strongly predict whether a generic launch will be enjoined?
3. How do claim construction outcomes typically affect ANDA patent cases?
4. Can an ANDA filer avoid liability by changing formulation or labeling during litigation?
5. How do co-pending ANDA cases involving the same Orange Book patents influence settlement leverage?

---

References (APA)

1. U.S. Code 35 U.S.C. § 271(e)(2).